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The insulin and insulin-like growth factor receptor (lR and IGF-l R respectively) networks are 
ancient and fundamental systems that control growth and metabolism in multicellular organisms. 
This thesis has examined several aspects of this field focusing on mammalian receptor biology 
and a comparison of the similarities and differences between the insulin and IGF receptor 
signalling systems. 
The insulin receptor family of proteins consist of eleven structural domains , of which the 
extracellular domains contain all the ligand binding and specificity detenninants. The insert 
domain, within the extracellular region is the least understood of all the domains, and it has no 
similarity to any other protein sequence. It does however contain the cleavage site which 
separates the receptor into two subunits and also a small stretch of residues shown to directly 
contact bound ligand and which is absolutely required for ligand binding in short recombinant 
fonns of the receptor. In addition, the human insulin receptor, expressed as one of two isofonns, 
A and B, results in the exclusion or inclusion of 12 amino acids directly adjacent to the ligand 
contacting amino acids in the inselt domain. The A isofonn lacking exon11 is expressed 
ubiquitously and the B isoform containing exonl l is co-expressed mainly in the traditional 
insulin responsive tissues of liver, muscle, adipocytes and kidney, where it is the dominant 
isofonn. 
In this thesis recombinant insert domain was expressed in a bacterial system in an attempt to 
purify folded protein suitable for NMR stJUctural analysis. The results of the expression studies 
indicated that the insert domain was unstructured in isolation and was unable to be adequately 
refolded by all conditions hied, although hydrophobic conditions appeared to partially stabilize 
the stJUcture. The overall conclusions of this project were that the Insert domain is likely to have 
limited structure, and probably buried within the receptor, and therefore requires the presence of 
the rest of the extracellular domains to adopt its COlTect structure. 
A comparison of the ligand binding and phsophorylation potential between the two human 
isoforms of the insulin receptor was made. A competition binding assay using europium labelled 
insulin was developed, that found that both IGF-l and IGF-2 had an increased affinity for the 
hIR-A, but insulin had a slightly reduced affinity. These results differ from the established 
literature in the raw values, however the relative ratios of binding strength are consistent. The 
most likely reason for this is that the europium labelled insulin has a different mode of binding 
the receptors due to the location of the europium chelate. Interestingly, using europium labelled 
IGF-l produced results nearly identical to those of conventional competition assays. 
Phosphorylation assays indicated that the hIR-B isofonn was more responsive than hIR-A. Even 
though IGF-2 and IGF-l had improved affinity for hIR-A, the level of phosphorylation was not 
as high. The ability of each growth factor to promote cellular proliferation con·elated well with 
the relative strength of binding and activation of the receptor. 
The regions of the IR and IGF-IR involved in binding substrates and regulators are 
predominantly found in the juxtamembrane domain and the C-terminal domain, which contain 
several potential tyrosine and serine phosphorylation target sequences. In this study the effect of 
mutations in unique tyrosine residues and other residues in the C-terminal domain of the hIGF­
lR was investigated. Results of time-course phosphorylation assays showed that mutation of 
'25 , Tyrosine to phenylalanine caused hyperphosphorylation of the receptor and increased 
'25oproliferation, which was caused by deregulation of a tyrosine phosphatase. A Tyrosine to 
phenylalanine mutation had altered kinetics of phosphorylation, displaying an unchanging rate of 
phosphorylation over time after ligand stimulation. However, proliferation was unaltered, 
indicating that even under extended exposure to ligand, the initial strength of receptor activation 
is more critical to affecting the biological response. 
The Caenorhabditis elegans insulin-like peptide family is a very large family consisting of 
possibly 38 peptides likely to be both agonists and antagonists of Daf-2 Receptor (IR homologue) 
signalling. Comparative modelli ng of all 38 peptides was performed based on the known 
structures of mammalian peptides. The overall results indicated that good quality models of ins 
peptides could be made despite the low sequence similarity with the templates. This suggested 
that it is the confonnational shape of the molecule allowable by the individual residues that is 
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